醫思健康(02138.HK)料全年銷售額按年增長至少35%
醫思健康(02138.HK)公布,預期截至3月底止全年銷售額將不少於30億元,按年增長不少於35%,上半年升63%,下半年則升15%。
當中,香港醫療服務全年銷售額按年上升不少於55%;香港及澳門醫學美容及美容服務則升不少於15%。內地全年銷售額升不少於18%。
展望未來,集團對其業務表現持樂觀態度,預期將受益於近期政府推出電子消費券計劃帶動下的本地零售市場復甦;對疫情相關醫療服務,包括但不僅限於身體檢查,核酸測試及抗體檢測的持續需求;新冠疫苗接種及外展服務的持續需求;遠程醫療服務的普及和需求提升;及市場的持續整合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.